Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside
The DOI matches its Crossref record; 144 of the 147 references it cites were found in a registry or an index.
Abstract
Characterization of mice with cell-specific deletion or overexpression of the mineralocorticoid receptor (MR) shed a new light on its role in health and disease. Pathophysiological MR activation contributes to a plethora of deleterious molecular mechanisms in the development of cardiorenal diseases like chronic kidney disease (CKD) and heart failure (HF). Accordingly, the available steroidal MR antagonists (MRAs) spironolactone (first generation MRA) and eplerenone (second generation MRA) have been shown to be effective in reducing cardiovascular (CV) mortality and morbidity in patients with chronic HF and a reduced left ventricular ejection fraction (HFrEF). However, they remain underutilized, in large part owing to the risk inducing severe adverse events including hyperkalemia and worsening of kidney function, particularly when given on top of inhibitors of the renin angiotensin system (RAS) to patients with concomitant kidney dysfunction. Novel, potent, and selective non-steroidal MRAs (third generation) were identified in drug discovery campaigns and a few entered clinical development recently. One of these is finerenone with different physicochemical, pharmacokinetics, and pharmacological properties in comparison with the steroidal MRAs. Available data from five clinical phase II trials with finerenone in more than 2,000 patients with HF and additional CKD and/or diabetes as well as in patients with diabetic kidney disease demonstrated that neither hyperkalemia nor reductions in kidney function were limiting factors to its use. Moreover, finerenone demonstrated a nominally improved outcome compared to eplerenone in a phase IIb trial with 1,066 patients with HFrEF and concomitant type 2 diabetes mellitus (T2DM) and/or CKD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Finerenone is a novel, selective, nonsteroidal MR antagonist (MRA) that blocks MR-mediated sodium reabsorption and MR overactivation and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical kidney and cardiovascular disease models.8 , 9”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [9]
In the citing paper
“As a nonsteroidal, selective mineralocorticoid receptor antagonist, finerenone has been shown to have potent anti-inflammatory and antifibrotic effects while reducing the urinary albumin-to-creatinine ratio, which may be related to its benefits in renal outcome and HHF [67–70].”
In the citing paper
“As a nonsteroidal, selective mineralocorticoid receptor antagonist, finerenone has been shown to have potent anti-inflammatory and antifibrotic effects while reducing the urinary albumin-to-creatinine ratio, which may be related to its benefits in renal outcome and HHF [67–70].”
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citation2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Self-citationTrends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction
Owan, T. E., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052256 · Cited by 4,191
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8807 · Cited by 3,304
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citation
Research works printed but not linked: 5
- Ergueden JK, Kolkhof P, Sandner P, Kuhl A, Stasch JP, Pook E, Schlemmer KH (2005) Fluorenone 1, 4,-dihydropyridin derivatives, WO/2005/087740. Bayer Healthcare AG, Wuppertal
- Kolkhof P, Flamme I, Figueroa-Pérez S, Baerfacker L, Hartmann E, Rinke M, Schäfer S (2006) Cardiac and renal protection by a new mineralocorticoid receptor antagonist in salt-sensitive hypertension [abstract P754]. Eur Heart J 27(Suppl 1):110
- Mulder P, BarreraChimal J, El Moghrabi S, Kolkhof P, Ouvrard-Pascaud A, Jaisser F (2016) Finerenone improves diastolic function in a preclinical model of type2 diabetes mellitus. Eur Heart J 37(Abstract Supplement):829
- Platt D, Pauli H (1972) Studies on organ- and subcellular distribution of [3H]spironolactone in animals [in German]. Arzneimittelforschung 22:1801–1802
- Simpson SA, Tait JF (1953) Memoirs of the Society for Endocrinology, No. 2. The determination of adrenal cortical steroids and their metabolites. Dennis Dobson, Ltd., London, p 9
Cited by
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationAgarwal, R., Filippatos, G., Pitt, B., Anker, S. D., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Gebel, M., Ruilope, L. M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab777 · Cited by 1,317
“Finerenone is a novel, selective, nonsteroidal MR antagonist (MRA) that blocks MRmediated sodium reabsorption and MR overactivation and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical kidney and cardiovascular disease models.(8,9) The FInerenone in reducing kiDnEy faiLure and dIsease prOgre…”
Self-citationMolecular mechanisms and therapeutic targets for diabetic kidney disease
Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.012 · Cited by 668
Self-citationSteroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Agarwal, R., Kolkhof, P., Bakris, G., Bauersachs, J., Haller, H., Wada, T., & Zannad, F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa736 · Cited by 638
Self-citationDiabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
Naaman, S. C., & Bakris, G. L. (2023) · Diabetes Care · doi:10.2337/dci23-0030 · Cited by 292
Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes
Filippatos, G., Anker, S. D., Agarwal, R., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Schloemer, P., Tornus, I., Joseph, A., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051898 · Cited by 294
Self-citationMineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
Barrera-Chimal, J., Girerd, S., & Jaisser, F. (2019) · Kidney International · doi:10.1016/j.kint.2019.02.030 · Cited by 261
Self-citationKolkhof, P., & Bärfacker, L. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0600 · Cited by 262
Self-citationRuilope, L. M., Agarwal, R., Anker, S. D., Bakris, G. L., Filippatos, G., Nowack, C., Kolkhof, P., Joseph, A., Mentenich, N., Pitt, B., et al. (2019) · American Journal of Nephrology · doi:10.1159/000503712 · Cited by 214
Self-citationNovel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Kintscher, U., Bakris, G. L., & Kolkhof, P. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15747 · Cited by 173
Self-citationRossing, P., Filippatos, G., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Chan, J. C. N., Kooy, A., McCafferty, K., Schernthaner, G., et al. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2021.10.008 · Cited by 156
“In contrast, finerenone has no effect on blood glucose, and its kidney-protective effect is driven by its anti-inflammatory and antifibrotic mode of action, translated from preclinical models, in concert with natriuresis.(28,29) Preclinical data support the hypothesis that complementary mechanisms of action between fi…”
Self-citationKolkhof, P., Hartmann, E., Freyberger, A., Pavkovic, M., Mathar, I., Sandner, P., Droebner, K., Joseph, A., Hüser, J., & Eitner, F. (2021) · American Journal of Nephrology · doi:10.1159/000516213 · Cited by 143
Self-citationChaudhuri, A., Ghanim, H., & Arora, P. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14601 · Cited by 120
“hypothesized mechanisms include increased MR expression in target tissues, elevated tissue levels of MR steroid hormone agonists (aldosterone and cortisol), and increased expression of non-classical MR activator Rac1.(47,60) Overactivation of the MR may also elevate CV and renal risks via haemodynamic and metabolic pa…”
BackgroundDapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists
Shen, L., Kristensen, S. L., Bengtsson, O., Böhm, M., de Boer, R. A., Docherty, K. F., Inzucchi, S. E., Katova, T., Køber, L., Kosiborod, M., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2020.11.009 · Cited by 128
Agarwal, R., Pitt, B., Palmer, B. F., Kovesdy, C. P., Burgess, E. D., Filippatos, G. S., Małyszko, J., Ruilope, L. M., Rossignol, P., Rossing, P. R., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac234 · Cited by 124
Self-citationAgarwal, R., Anker, S. D., Bakris, G., Filippatos, G., Pitt, B., Rossing, P., Ruilope, L., Gebel, M., Kolkhof, P., Nowack, C., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa294 · Cited by 103
“Emerging data from Phase II trials with finerenone in patients with heart failure and patients with CKD and T2D demonstrate that neither hyperkalemia nor reductions in kidney function were limiting factors to its use [15].”
BackgroundInfluentialSelf-citationMineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis
Tesch, G. H., & Young, M. J. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00313 · Cited by 119
“The development of MRAs has recently been reviewed in detail (Kolkhof et al., 2016).”
BackgroundAgarwal, R., Tu, W., Farjat, A. E., Farag, Y. M. K., Toto, R., Kaul, S., Lawatscheck, R., Rohwedder, K., Ruilope, L. M., Rossing, P., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m23-1023 · Cited by 109
“Mineralocorticoid receptor activation in those with CKD and T2D is associated with kidney damage and is re fl ected by kidney injury captured by an increase in UACR (31, 32).”
BackgroundSelf-citationBlood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes
Ruilope, L. M., Agarwal, R., Anker, S. D., Filippatos, G. S., Pitt, B., Rossing, P. R., Sarafidis, P. A., Schmieder, R. E., Joseph, A., Rethemeier, N., et al. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19744 · Cited by 118
Self-citationEffect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
Agarwal, R., Ruilope, L. M., Ruiz‐Hurtado, G., Haller, H. G., Schmieder, R. E., Anker, S. D., Filippatos, G. S., Pitt, B., Rossing, P. R., Lambelet, M., et al. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003330 · Cited by 117
“Our study demonstrates that once-daily administration of finerenone effectively reduced 24-h ambulatory BP, suggesting that the transcriptional effects of the drug, rather than its short half-life, might be more important in modulating this effect [23].”
BackgroundSelf-citationZhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01676-5 · Cited by 96
“As a nonsteroidal, selective mineralocorticoid receptor antagonist, nerenone has been shown to have potent anti-in ammatory and anti brotic effects while reducing the urinary albumin-to-creatinine ratio, which may be related to its bene ts in renal events and HHF [66-69].”
BackgroundEpstein, M. (2021) · American Journal of Nephrology · doi:10.1159/000515622 · Cited by 102
Kolkhof, P., Joseph, A., & Kintscher, U. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105859 · Cited by 94
Self-citationRole of Aldosterone and Mineralocorticoid Receptor in Cardiovascular Aging
Gorini, S., Kim, S. K., Infante, M., Mammi, C., Vignera, S. L., Fabbri, A., Jaffe, I. Z., & Caprio, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00584 · Cited by 94
Self-citationLavall, D., Jacobs, N., Mahfoud, F., Kolkhof, P., Böhm, M., & Laufs, U. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.07.001 · Cited by 82
Self-citationMarzolla, V., Feraco, A., Gorini, S., Mammi, C., Marrese, C., Mularoni, V., Boitani, C., Lombès, M., Kolkhof, P., Ciriolo, M. R., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202000164r · Cited by 80
Self-citationGerisch, M., Heinig, R., Engelen, A., Lang, D., Kolkhof, P., Radtke, M., Platzek, J., Lovis, K., Rohde, G., & Schwarz, T. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.083337 · Cited by 72
“10 mM) with different physicochemical, pharmacokinetic, and pharmacological properties (Kolkhof et al., 2015, 2017).”
BackgroundSelf-citationDroebner, K., Pavkovic, M., Grundmann, M., Hartmann, E., Goea, L., Nordlohne, J., Klar, J., Eitner, F., & Kolkhof, P. (2021) · American Journal of Nephrology · doi:10.1159/000518254 · Cited by 77
Self-citationGenomic and rapid effects of aldosterone: what we know and do not know thus far
Hermidorff, M. M., de Assis, L. V. M., & Isoldi, M. C. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9591-2 · Cited by 75
“The role of MR in the cardiomyocytes, endothelial, and vascular smooth muscle cells, fibroblasts, and macrophages has been recently and elegantly addressed elsewhere [24].”
BackgroundKidney Fibrosis and Oxidative Stress: From Molecular Pathways to New Pharmacological Opportunities
Patera, F., Gatticchi, L., Cellini, B., Chiasserini, D., & Reboldi, G. (2024) · Biomolecules · doi:10.3390/biom14010137 · Cited by 77
“The most effective is finerenone, which behaves as an inverse agonist and inhibits cofactor recruitment to MRs in the ligand-free state [72].”
BackgroundMutruc, V., Bologa, C., Șorodoc, V., Ceasovschih, A., Morărașu, B. C., Șorodoc, L., Catar, O., & Lionte, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082833 · Cited by 89
“Kidney and heart diseases are associated with mineralocorticoid receptor overactivation [42], with increased gene expression of NADPH oxidase, pro-inflammatory cytokines, and pro-fibrotic mediators [43].”
Kolkhof, P., Lawatscheck, R., Filippatos, G. S., & Bakris, G. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169243 · Cited by 72
“Preclinical evidence describing the mode of action of steroidal and nonsteroidal MRAs in models of cardiorenal disease has been previously reviewed [23]; however, evidence on the components of the mechanism of action of finerenone across a variety of organ systems is rapidly growing.”
BackgroundSelf-citationHyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies
Valdivielso, J. M., Balafa, O. C., Ekart, R., Ferro, C. J., Mallamaci, F., Mark, P. B., Rossignol, P., Sarafidis, P. A., Vecchio, L. D., & Ortíz, A. (2021) · Drugs · doi:10.1007/s40265-021-01555-5 · Cited by 62
Kintscher, U., & Edelmann, F. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01899-0 · Cited by 62
“Finerenone Finerenone is a novel non-steroidal MRA with high binding affinity (IC50: 18nM) and high MR selectivity over sex steroid hormone receptors, thereby lacking anti-androgenic and progestational side effects (Table 1) [9, 22].”
BackgroundBarrera‐Chimal, J., Kolkhof, P., Lima‐Posada, I., Alexandre, J., Rossignol, P., & Jaisser, F. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.2002844 · Cited by 54
Self-citationHeinig, R., Gerisch, M., Engelen, A., Nagelschmitz, J., & Loewen, S. (2018) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-018-0483-9 · Cited by 55
Banerjee, M., Maisnam, I., Pal, R., & Mukhopadhyay, S. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad522 · Cited by 51
Aldosterone and Aldosterone Modulation in Cardio-Kidney Diseases
Fioretti, F., Testani, J. M., Tio, M. C., Pitt, B., & Butler, J. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.012 · Cited by 56
Self-citationMcGill, J. B., Haller, H. G., Roy‐Chaudhury, P., Cherrington, A., Wada, T., Wanner, C., Ji, L., & Rossing, P. R. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-002806 · Cited by 57
Mineralocorticoid Antagonism and Diabetic Kidney Disease
Lytvyn, Y., Godoy, L. C., Scholtes, R. A., van Raalte, D. H., & Cherney, D. Z. I. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1123-8 · Cited by 52
Rossing, P. R., Agarwal, R., Anker, S. D., Filippatos, G. S., Pitt, B., Ruilope, L. M., Fonseca, V. A., Umpierrez, G. E., Caramori, M. L., Joseph, A., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14883 · Cited by 50
Self-citationLerma, E. V., & Wilson, D. J. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2094770 · Cited by 46
“accumulation of spironolactone and eplerenone are observed in the kidney than in the heart tissues (at least six-fold and three-fold, respectively) [41].”
BackgroundInfluentialLerma, E., White, W. B., & Bakris, G. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2022.2060598 · Cited by 39
“tion are effects of MRA activity in the kidneys [24].”
BackgroundSueta, D., Yamamoto, E., & Tsujita, K. (2020) · Current Hypertension Reports · doi:10.1007/s11906-020-1023-y · Cited by 40
“These policies have been comprehensively reviewed [100].”
Zhai, S., Ma, B., Chen, W., & Zhao, Q. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1476029 · Cited by 53
Meta-Analysis of the Efficacy and Safety of Finerenone in Diabetic Kidney Disease
Zheng, Y., Ma, S., Huang, Q., Yu, F., Tan, H., Chen, Y., & Li, C. (2022) · Kidney & Blood Pressure Research · doi:10.1159/000521908 · Cited by 40
Bansal, S., Canziani, M. E. F., Birne, R., Anker, S. D., Bakris, G. L., Filippatos, G. S., Rossing, P. R., Ruilope, L. M., Farjat, A. E., Kolkhof, P., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-076444 · Cited by 40
Self-citationThe Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
Heinig, R., & Eißing, T. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01312-9 · Cited by 47
“Based on the physiological role of aldosterone and MR in electrolyte homeostasis, increasing serum potassium is a result of the mode of action of MRAs [1].”
BackgroundInfluentialMineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
Baran, W., Krzemińska, J., Szlagor, M., Wronka, M., Młynarska, E., Franczyk, B., & Rysz, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189995 · Cited by 39
“with ejection fraction (EF) of MRA in patients with heart failure (HF) [6].”
Backgroundde Cos, M., Xipell, M., García‐Herrera, A., Lledó, G. M., Guillén, E., Blasco, M., Espinosa, G., Cervera, R., & Quintana, L. F. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.103014 · Cited by 33
Approaches towards tissue‐selective pharmacology of the mineralocorticoid receptor
Clarisse, D., Deng, L., Bosscher, K. D., & Lother, A. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15719 · Cited by 31
Heinig, R., Lambelet, M., Nagelschmitz, J., Alatrach, A., & Halabi, A. (2019) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-019-00547-x · Cited by 28
Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice
Desai, N. R., Navaneethan, S. D., Nicholas, S. B., Pantalone, K. M., Wanner, C., Hamacher, S., Gay, A., & Wheeler, D. C. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108411 · Cited by 34
“21 Guidance from the US and European labels for finerenone recommend withholding finerenone if serum potassium exceeds 5.5 mEq/L (5.5 mmol/L) and restarting treatment with finerenone 10 mg when serum potassium is ≤ 5.0 mEq/L (5.0 mmol/L).”
InfluentialSridhar, V. S., Limonte, C. P., Groop, P., Heerspink, H. J. L., Pratley, R. E., Rossing, P. R., Skyler, J. S., & Cherney, D. Z. I. (2023) · Diabetologia · doi:10.1007/s00125-023-06015-1 · Cited by 34
“Over the last few years, novel non-steroidal MRAs such as finerenone have been developed that demonstrate greater mineralocorticoid receptor selectivity and other pharmacokinetic differences compared with steroidal MRAs [67].”
BackgroundClinical implications of mineralocorticoid receptor overactivation
Mouhayyar, C. E., Chhikara, M., Tang, M., & Nigwekar, S. U. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae346 · Cited by 26
“The MR, a ligand-activated nuclear transcription factor, is expressed in diverse cell types throughout the body, including the gastrointestinal tract, heart, brain, kidneys, immune cells, and vasculature [6 ].”
Management and Outcomes of Primary Aldosteronism in Pregnancy: A Systematic Review
Sanga, V., Rossitto, G., Seccia, T. M., & Rossi, G. P. (2022) · Hypertension · doi:10.1161/hypertensionaha.121.18858 · Cited by 26
Rohde, G., Loewen, S., & Heinig, R. (2021) · Journal of Chromatography B · doi:10.1016/j.jchromb.2021.122643 · Cited by 25
Zhang, H., Xie, J., Hao, C., Li, X., Zhu, D., Zheng, H., Xu, X., Mo, Z., Lu, W., Lu, Y., et al. (2023) · Kidney Diseases · doi:10.1159/000531997 · Cited by 22
Targeting apoptosis signal‐regulating kinase 1 in acute and chronic kidney disease
Tesch, G. H., Ma, F. Y., & Nikolic‐Paterson, D. J. (2020) · The Anatomical Record · doi:10.1002/ar.24373 · Cited by 19
Heinig, R., Gerisch, M., Bairlein, M., Nagelschmitz, J., & Loewen, S. (2020) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-020-00610-y · Cited by 20
Renin–angiotensin system blockade: Finerenone
Ruilope, L. M., & Tamargo, J. L. (2017) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2017.02.003 · Cited by 21
“Thus, a combined renal Na excretion and a mild K retention are clearly beneficial and demanded characteristics [33,34].”
BackgroundInfluentialPerakakis, N., Bornstein, S. R., Birkenfeld, A. L., Linkermann, A., Demir, M., Anker, S. D., Filippatos, G. S., Pitt, B., Rossing, P. R., Ruilope, L. M., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15305 · Cited by 25
“9,10 Finerenone, a selective, nonsteroidal mineralocorticoid receptor (MR) antagonist (MRA) that inhibits MR overactivation, 11 – 16 was recently approved to slow the progression of CKD and reduce the risk of CV events in adults with CKD associated with T2D.”
BackgroundSelf-citationProgress in the Management of Primary Aldosteronism
Morimoto, R., Omata, K., Ito, S., & Satoh, F. (2018) · American Journal of Hypertension · doi:10.1093/ajh/hpy018 · Cited by 18
Marzolla, V., Infante, M., Armani, A., Rizzo, M., & Caprio, M. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2130889 · Cited by 21
“between groups, suggesting a mainly nonhemodynamic effect of finerenone, possibly caused by an effect of finerenone improving cardiovascular and kidney inflammation and fibrosis, as demonstrated in preclinical studies [22,49,60,78].”
BackgroundHan, Y., Xian, Y., Gao, X., Qiang, P., Hao, J., Yang, F., Shimosawa, T., Chang, Y. Y., & Xu, Q. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109396 · Cited by 17
Yao, L., Liang, X., & Wang, P. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00022.2023 · Cited by 22
Chen, X., Li, X., Zhang, K., Lian, K., Zhang, W., Song, Y., Kan, C., Zhang, J., Han, F., Sun, X., et al. (2023) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02413-2 · Cited by 19
“For instance, studies have shown that finerenone dose-dependently reduced the renal mRNA expression of PAI-1, MCP-1, and MMP-2 [12, 57].”
Epstein, M., & Freundlich, M. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab254 · Cited by 18
The interplay between heart failure and chronic kidney disease
Lala, A., Levin, A., & Khunti, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16371 · Cited by 22
Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease
Górriz, J. L., González‐Juanatey, J. R., Fácila, L., Soler, M. J., Valle, A., & Ortíz, A. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.09.002 · Cited by 18
Cardiovascular Efficacy and Safety of Finerenone: A Meta‐Analysis of Randomized Controlled Trials
Ahmed, M., Ahsan, A., Shafiq, A., Maniya, M. T., Jain, H., Iqbal, J., Naveed, M. A., Ahmed, R., Rana, J. S., Fudim, M., et al. (2025) · Clinical Cardiology · doi:10.1002/clc.70065 · Cited by 20
“The benefits observed in HF ‐ related outcomes are consistent with the cardioprotective effects of MRAs [22, 23], highlighting finerenone as an effective agent in reducing the burden of HF exacerbations.”
Mineralocorticoid receptor antagonists in cardiovascular translational biology
CHILTON, R. J., & Silva‐Cardoso, J. (2023) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000289 · Cited by 17
Selective endothelin A receptor antagonism in patients with proteinuric chronic kidney disease
Provenzano, M., Andreucci, M., Garofalo, C., Minutolo, R., Serra, R., & Nicola, L. D. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1869720 · Cited by 14
“come the serious adverse events of previous steroidal MRA such as spironolactone and eplerenone which cause hyperkalemia, gynecomastia, female menstrual disorders and worsening kidney function limiting their use in clinical practice [70,71].”
BackgroundWu, J., Tseng, K., & Lin, Y. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.043373 · Cited by 15
“11 Furthermore, a recent randomized controlled trial demonstrated that finerenone significantly reduced the risk of the primary composite outcome of total worsening HF events and cardiovascular death in patients with HFmrEF or HFpEF compared with placebo.”
Arici, M., ALTUN, B., Araz, M., Atmaca, A. A., Demir, T., Ecder, T., Güz, G., Yavuz, D. G., Yildiz, A., & Yilmaz, T. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1384454 · Cited by 19
Report from the CVOT Summit 2020: new cardiovascular and renal outcomes
Schnell, O., Cos, X., Cosentino, F., Forst, T. M., Giorgino, F., Heersprink, H. J. L., Kosiborod, M., Wanner, C., & Standl, E. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01254-1 · Cited by 15
Dutta, D., Surana, V., Bhattacharya, S., Aggarwal, S., & Sharma, M. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_376_21 · Cited by 13
“[8] Finerenone has been shown to have a more potent anti‐inflammatory and antifibrotic effects than steroidal MRAs in preclinical studies.[9] In a meta‐analysis published in 2018 involving people living with heart failure, finerenone was shown to have a beneficial impact on reducing circulating levels of NT‐proBNP and…”
BackgroundKintscher, U. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01998-0 · Cited by 12
“Based on their binding mode to the MR-LBD, both steroidal MRA are named “pas-sive” MRAs, meaning that they mediate an unstable receptor conformation resulting in an ineffective binding of MR co-repressors [1 •• , 15].”
Zhou, M.-S., Zheng, S.-Y., Chen, C., Li, X., Zhang, Q., Zhao, Y., & Zhang, W. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115975 · Cited by 11
The potential role of finerenone in patients with type 1 diabetes and chronic kidney disease
Vasco, M. A. E., Fantaye, S. H., Raghunathan, S., & Solis‐Herrera, C. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15773 · Cited by 13
Chen, X., Huang, M., Chen, Y., Xu, H., & Wu, M. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10455-1 · Cited by 13
“This contrasts with eplerenone and spironolactone, which are at least three times more concentrated in the kidney than in the heart, whereas spironolactone is more concentrated in the kidney and below the limit of detection in the heart [95].”
Yang, S., Shen, W., Zhang, H.-Z., Wang, C., Yu, W., & Wu, Q. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001364 · Cited by 14
The Mechanisms of Actions of Aldosterone and its Antagonists in Cardiovascular Disease
Pantelidis, P., Sideris, M. C., Viigimaa, M., Avranas, K., Deligkaris, P., Zografou, I., & Lović, D. B. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190215100502 · Cited by 12
Zhang, Y., Wang, J., Jiang, L., Wang, T., Li, Z., Fu, X., Huang, W., Xiao, Y., Wang, S., & Zhao, J. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00929-3 · Cited by 11
“Although finerenone has been shown smaller effects on serum potassium levels than spironolactone [49, 50], it was still associated with increased risk of SHK due to the antagonism of aldosterone receptors.”
BackgroundOrtíz, A., Arroyo, R. A., Escribano, P. P. C., Fernández‐Fernández, B., Debén, F. M., Mediavilla, J. D., Doña, A. M., Soler, M. J., & Górriz, J. L. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2213888 · Cited by 12
New perspectives in the management of diabetic nephropathy
Psyllaki, A., & Τζιόμαλος, Κ. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i6.1086 · Cited by 12
The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction
Papademetriou, V., Toumpourleka, M., Imprialos, K. P., Alataki, S., Manafis, A., & Stavropoulos, K. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190219141326 · Cited by 11
Mamazhakypov, A., & Lother, A. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1118516 · Cited by 11
Yasmin, F., Aamir, M. B., Najeeb, H., Atif, A. R., Siddiqui, A. H., Ahsan, M. N., Moeed, A., Ali, S. H., Tahir, H. M., & Asghar, M. S. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001180 · Cited by 14
Morales, J., & Palmer, B. F. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2316572 · Cited by 9
“Also, unlike sMRAs, which have active metabolites detectable in the urine several weeks after discontinuing therapy, nsMRAs have no active metabolites [50].”
BackgroundAdji, A. S., Widjaja, J. S., & de Liyis, B. G. (2024) · The Egyptian Heart Journal · doi:10.1186/s43044-024-00580-5 · Cited by 11
Soulié, M., Stéphan, Y., Durand, M., Lima‐Posada, I., Palacios, R., Nicol, L., López‐Andrés, N., Mulder, P. G. H., & Jaisser, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-74934-z · Cited by 11
Self-citationSodium Chloride Cotransporter in Hypertension
Castagna, A., Mango, G., Martinelli, N., Marzano, L. A., Moruzzi, S., Friso, S., & Pizzolo, F. (2024) · Biomedicines · doi:10.3390/biomedicines12112580 · Cited by 8
“In other words, the MRA-treated patients with lower basal values of renin (i.e., more severe volume expansion) were also those with a greater change in the expression of NCC mRNA, mirroring a greater NCC response to diuretic therapy [145].”
Water and electrolyte abnormalities in novel pharmacological agents for kidney disease and cancer
Terashita, M., Yazawa, M., Murakami, N., Nishiyama, A., Electrolyte Winter Seminar Collaborative Group, Fujimaru, T., Fujita, Y., Hirose, K., Kawada, K., Monkawa, T., et al. (2025) · Clinical and Experimental Nephrology · doi:10.1007/s10157-025-02635-6 · Cited by 8
“Finerenone has a shorter half-life compared to spironolactone, whose active metabolites persist for over 12 h in healthy individuals and even longer in patients with CKD or heart failure [45, 46].”
Virani, S., Zieroth, S. R., Aleksova, N., Anderson, K., Clarke, B., Ducharme, A., Ezekowitz, J. A., Foroutan, F., Giannetti, N., Jain, R., et al. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.07.027 · Cited by 34
RetractedXu, X., Feng, J., Cui, Y., Li, P., Dong, J., & Liao, L. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13566 · Cited by 8
“30,31 Nonsteroidal MRAs have emerged as a new therapeutic tool targeting systemic impact.”
BackgroundLiu, K., Kurukulasuriya, R., Dykstra, K. D., DiMichele, L. M., Liu, J., Váchal, P., Ogawa, A. K., DeVita, R. J., Shen, D., Tan, Q., et al. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.04.024 · Cited by 7
Finerenona: completando el abordaje del paciente con enfermedad renal y diabetes
Górriz, J. L., González‐Juanatey, J. R., Fácila, L., Soler, M. J., Valle, A., & Ortíz, A. (2022) · Nefrología · doi:10.1016/j.nefro.2022.09.002 · Cited by 14
Potential Impact of Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiovascular Disease
Rahman, A., Jahan, N., Rahman, M. T., & Nishiyama, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031922 · Cited by 9
Metadata
- Authors
- Kolkhof, P., Jaisser, F., Kim, S.-Y., Filippatos, G., Nowack, C., & Pitt, B.
- Affiliations
- Bayer (Germany) (DE)
- National and Kapodistrian University of Athens (GR)
- University of Michigan (US)
- Corresponding author
- Kolkhof, Peter
- Venue
- Handbook of Experimental Pharmacology
- Publisher
- Springer International Publishing
- Published
- 2016
- Volume
- 243
- Pages
- 271-305
- ISSN
- 0171-2004 (ISSN-L)
- 1865-0325
- OpenAlex
- W2555239285
- Cited by
- 180
- References
- 147
- Citations by year
- 2026: 22 · 2025: 25 · 2024: 22 · 2023: 23 · 2022: 28 · 2021: 20 · 2020: 16 · 2019: 14 · 2018: 6 · 2017: 3 · 2016: 1
- FWCI
- 33.76
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Handbook of experimental pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- mineralocorticoid receptor antagonists, finerenone, spironolactone, eplerenone, heart failure with reduced ejection fraction, chronic kidney disease, cardiorenal disease, diabetic nephropathy, hyperkalemia, renin-angiotensin system inhibitors, type 2 diabetes, non-steroidal MRAs, drug safety and efficacy
- MeSH terms
- Eplerenone, Mineralocorticoid Receptor Antagonists, Animals, Diabetic Nephropathies, Fibroblasts, Heart Failure, Humans, Macrophages, Muscle, Smooth, Vascular, Naphthyridines, Spironolactone, Stroke Volume, Receptors, Mineralocorticoid, Myocytes, Cardiac, Myocytes, Smooth Muscle, Endothelial Cells, Cardio-Renal Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.